Active LitigationMDL 3081
Bard PowerPort Lawsuit Facts
TorHoerman Law is actively accepting claims for the Bard PowerPort Lawsuit.
Thousands of individuals with an implant port system implanted for long-term vascular access have come forward alleging injuries linked to Bard’s vascular access devices.
These cases form the basis of the growing Bard PowerPort catheter lawsuits, which argue that the device’s catheter material and port design created preventable risks that were not adequately disclosed.
As filings increased nationwide, the Judicial Panel on Multidistrict Litigation centralized all federal cases into MDL No. 3081.
The Bard PowerPort MDL was assigned to Judge David Campbell in the U.S. District Court for Arizona..
This structure allows one court to manage shared evidence, coordinate expert evaluations, and resolve pretrial issues efficiently across thousands of pending lawsuits.
The litigation is now advancing through the discovery process, where both sides exchange documents, analyze device testing, depose experts, and inspect explanted PowerPort components.
As of January 2026, there are 2,325 lawsuits pending in the Bard PowerPort multidistrict litigation (MDL).
The first federal bellwether trial in the Bard PowerPort MDL is scheduled for April 21, 2026.
The Bard PowerPort MDL is expected to continue growing, with more cases being filed as awareness of the risks increases.
Plaintiffs describe a wide range of medical complications, including infections, blood clots, catheter fractures, and migration of broken components into major vessels.
Bard PowerPort claims involve complex engineering, medical, and regulatory questions, making the centralized MDL essential for consistent oversight.
Bard PowerPort lawsuit allegations include:
- Failure to design a safe and durable implantable port and catheter system.
- Use of materials susceptible to cracking, fracturing, and internal degradation over time.
- Failure to perform adequate testing to identify long-term device risks.
- Failure to adequately warn healthcare providers and patients of known dangers.
- Marketing the product as reliable for repeated high-pressure injections despite structural vulnerabilities.
- Negligent manufacturing practices contributing to variability and premature device failure.
As the MDL progresses, Bard PowerPort trials will help evaluate how juries respond to the evidence presented and may influence future settlement discussions.
Although no global resolution has been reached, the ongoing litigation continues to shape the legal and medical understanding of the injuries associated with Bard’s port systems.
What Bard PowerPort Devices are Included in the PowerPort Catheter Lawsuit?
The lawsuits involve multiple models of the Bard implanted port catheter, all designed to deliver long-term vascular access for patients who require repeated infusions.
These devices are widely used among cancer patients undergoing chemotherapy, making reliability and structural integrity essential for safe treatment.
Plaintiffs allege that defects in the catheter material and port housing have caused fractures, migration, infections, and other complications across several product lines.
The claims also argue failure to adequately warn patients and medical providers about the risks associated with each Bard PowerPort catheter device.
Because the reported issues span multiple versions of the port system, several models have been named in the litigation.
Specific Bard PowerPort devices included in the lawsuit may include:
- Slim Implantable Port PowerPort
- ISP implantable port PowerPort
- PowerPort ClearVUE Implantable Ports
- PowerPort M.R.I. Implantable Port
- PowerPort Implantable Port (general family)
A new lawsuit filed in February 2026 alleges that a defective Bard PowerPort ISP M.R.I. Implantable Port caused severe medical complications for a plaintiff who received the port in March 2023.
The Bard PowerPort MDL has seen a significant increase in claims, with nearly 100 new plaintiffs joining since August 2023.
